Polatuzumab Vedotin

BATCH NUMBER: To be announced


Minimum order quantity: 4

Therapeutic Polatuzumab Vedotin antibody from the original Polivy® commercial drug

Drug Aliquots On Demand

*Subject to availability and market fluctuations.

Product specifications:​

  • Product Concentration 20 mg/mL
  • Volume per vial 100 µL
  • Quantity per vial 2 mg
  • Batch Number to be announced
  • Storage Temperature 2-8 °C / -80 °C
Our products are for research use only. The “therapeutic expiration date” implies expiry date for patient adminstration and is not applicable to the shelf life of the aliquot. Aliquot storage at -86°C ensures fully functional molecules even after the mentioned expiry date

Product Information:

Evidentic offers repackaged finished pharmaceutical products (e.g RMP/RLD). We refer to the repackaged RMP/RLD products synonymously as drug aliquots or aRMP, or short: aliquots.

We offer batches of original drug aliquots in low-binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.

As ‘raw material’ for the production of drug aliquots, Evidentic sources RMP from the European (EU) market. As a licensed pharmaceutical wholesaler, Evidentic is committed to Good Distribution Practice (GDP) compliance with respect to the procurement, storage and shipment of RMP.
Drug aliquots are manufactured by repackaging RMP in a qualified laboratory. The aliquotation process is performed under a quality and manufacturing agreement between Evidentic and the contract manufacturer. Repackaging of RMP includes the following steps: opening the secondary and primary RMP containers and transferring the specified volumes of RMP into an Eppendorf 0.5 ml low-binding (or similar) tube. If the RMP is a lyophilized powder and not a highly concentrated solution, reconstitute the RMP according to the original manufacturer’s instructions and then aliquot as a highly concentrated solution.
For identification purposes, drug aliquots are labeled with the date of aliquoting, the original lot number of the RMP, the original expiration date of the RMP, the name of the active ingredient (INN), and a unique identification code.
Immediately after aliquoting, drug aliquots are stored at either 2-8 °C or -86 °C for long-term storage. All drug aliquots stored at 2-8 °C are transferred to -86 °C at least two weeks before the expiration date of the original RLD/RMP is reached. Further quality or functional testing are not performed on the drug aliquots.  

Class of molecule


Host cells

Chinese hamster ovary (CHO) cells

Prepared from


Therapeutic Area

Therapeutic Indications

Mechanism of Action (MoA)

Polatuzumab vedotin is a CD79b-targeted antibody-drug conjugate that preferentially delivers a potentanti-mitotic agent (monomethyl auristatin E, or MMAE) to B-cells, which results in the killing ofmalignant B-cells. The polatuzumab vedotin molecule consists of MMAE covalently attached to ahumanized immunoglobulin G1 monoclonal antibody via a cleavable linker. The monoclonal antibodybinds with high affinity and selectivity to CD79b, a cell surface component of the B-cell receptor.CD79b expression is restricted to normal cells within the B-cell lineage (with the exception of plasmacells) and malignant B-cells; it is expressed in > 95% of diffuse large B-cell lymphoma. Upon bindingCD79b, polatuzumab vedotin is rapidly internalized and the linker is cleaved by lysosomal proteasesto enable intracellular delivery of MMAE. MMAE binds to microtubules and kills dividing cells byinhibiting cell division and inducing apoptosis.

Pharmacotherapeutic group​​

Antineoplastic agent

List of Excipients​

Succinic acid, Sodium hydroxide (for pH-adjustment), Sucrose, Polysorbate 20 (E 432)

Not looking for Polatuzumab Vedotin?

Search our therapeutic molecules product database

Evidentic Support
+49 (0) 30 959 99 8831

Let us know about your inquiry details and we’ll contact you shortly.

we are recruiting